Global Renal Hypertension Treatment Market - Industry Trends and Forecast to 2028

Market Analysis and Insights: Global Renal Hypertension Treatment Market

The renal hypertension treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.10% in the above-mentioned research forecast period. Increase in research related to the treatment of hypertension is the driving factor for the renal hypertension treatment market growth. For instance, the device paradise renal denervation system which is used for lowering the high blood pressure in which the catheter is placed inside the renal arteries produces the heat which will be useful for decreasing the blood pressure.  

Renal hypertension or renal artery stenosis is a kidney disorder which is characterized by the blockage or narrowing of the arteries that is responsible for carrying the blood to the kidney which leads to high blood pressure. The high blood pressure provides the stress to the blood vessels in the kidney along with the filtering units. Due to the pressure, the blood vessels become thick and the blood is not properly purified by the filtering units in the kidney. Therefore, high blood pressure can cause kidney failure.

Due to high prevalence of renovascular hypertension in the United States, there are 1-10% of the 50 million cases of the hypertension which act as a driver for the renal hypertension treatment market growth. Changes in the lifestyle of the population such as consumption of alcohol, high cholesterol food items, use of cocaine as a drug and smoking habit is also one of the factors for the renal hypertension treatment market growth. Increase in population having diseases such as high blood pressure and diabetes are the main factors for the renal hypertension treatment market growth. Increase in geriatric population which are mainly at the high risk of renal hypertension is the driver factor for the renal hypertension treatment market growth. However, complications related to the treatment of renal hypertension such as renal failure, myocardial infarction, left ventricular hypertrophy and congestive heart failure and complications and high risk during the surgery are the factors which act as restraint for the renal hypertension treatment market growth. Lack of treatment options for renal artery stenosis associated with fibromuscular dysplasia decreases the renal hypertension treatment market growth.     

This renal hypertension treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the renal hypertension treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Renal Hypertension Treatment Market Scope and Market Size

The renal hypertension treatment market is segmented on the basis of diagnosis, treatment, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of diagnosis, the renal hypertension treatment market is segmented into lab test and imaging test. Lab test is further segmented to blood test and urine test. Imaging test is further segmented to doppler ultrasound, CT scan, magnetic resonance angiography (MRA) and renal arteriography.
• On the basis of treatment, the renal hypertension treatment market is segmented into medication and procedures. Medication is further segmented to angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, beta blockers and alpha-beta blockers and calcium channel blockers. Angiotensin-converting enzyme (ACE) inhibitors are further sub-segmented to ramipril, benazepril, captopril, lisinopril and others. Angiotensin II receptor blockers (ARBs) is further sub-segmented to candesartan, losartan, olmesartan and valsartan. Procedures are further segmented to renal angioplasty, stenting and renal artery bypass surgery.
• On the basis of end user, the renal hypertension treatment market is segmented to hospitals, clinics and others.
• On the basis of distribution channel, the renal hypertension treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.

Global Renal Hypertension Treatment Market Country Level Analysis

Global renal hypertension treatment Market is analysed and market size information is provided by country, diagnosis, treatment, end user and distribution channel as referenced above.

The countries covered in the renal hypertension treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America including the United States and Canada are expected to hold the largest market share due to the growing cases of kidney disorder, presence of sophisticated medical facilities in order to maximize the treatment effectiveness of the kidney disease and increasing focus in the research and development activity. Europe has been witnessing the second largest regional segment for renal hypertension treatment market throughout the forecasted period owing to the high diagnostic rate and presence of key players in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The renal hypertension treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to renal hypertension treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the renal hypertension treatment market in the growth period.

Competitive Landscape and Renal Hypertension Treatment Market Share Analysis

The renal hypertension treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to renal hypertension treatment market.

The major players covered in the global renal hypertension treatment market report are AstraZeneca, F. Hoffmann-La Roche Ltd, AbbVie, Inc., Allergan, Amgen Inc., Hikma Pharmaceuticals plc, Zydus Cadila, Alkem Labs, Mylan N.V., Pfizer Inc, Novartis AG, Apotex Inc, Teva Pharmaceuticals Industries Ltd, Wockhardt, Mayne Pharma Group Limited, Calliditas Therapeutics AB, Merck KGaA, Astellas Pharma Inc among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-60054